Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 715.96B +16.8% |
| Revenue (ttm) | 47.38B +45.4% |
| Net Income | 14.68B +120.0% |
| EPS | 16.30 +121.0% |
| Shares Out | n/a |
| PE Ratio | 48.77 |
| Forward PE | 32.65 |
| Dividend | 5.01 (0.63%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | n/a |
| Average Volume | 3 |
| Open | n/a |
| Previous Close | 780.00 |
| Day's Range | n/a |
| 52-Week Range | 538.08 - 880.00 |
| Beta | 0.33 |
| RSI | 40.68 |
| Earnings Date | Feb 4, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive
Eli Lilly enters 2026 with strong commercial momentum, pipeline wins, and shares near all-time highs. The company's strategic price cuts for Zepbound and commitment to a low-priced launch of orforglip...
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion
Repertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE: LLY) to develop tolerizing therapies for multiple autoimmune diseases.
Trump says Eli Lilly to build six US plants
U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and that the company plans to build six plants in the country.
Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead.
AI could make it faster and easier to develop drugs. Eli Lilly is looking to lead this transformation.
Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based biotech said on Th...
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and commercialize treatments for hearing loss...
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its rival medicines,...
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M...
Up 36%, Is Eli Lilly Still a Buy?
Eli Lilly is at the forefront of both diabetes and obesity medications. The pharmaceutical giant has offered strong guidance for the end of 2025.
Where Will Eli Lilly Be in 10 Years?
The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle.
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?
Both companies may succeed in this industry.
A Look Into Eli Lilly and Co Inc's Price Over Earnings
Looking into the current session, Eli Lilly and Co Inc. (NYSE: LLY) shares are trading at $1060.01, after a 0.40% drop. Over the past month, the stock decreased by 1.76% , but over the past year, it ...
Lansing Street Advisors Sells 138 Shares of Eli Lilly and Co (LLY)
Lansing Street Advisors Sells 138 Shares of Eli Lilly and Co (LLY)
BCS Wealth Management Sells 655 Shares of Eli Lilly and Co (LLY)
BCS Wealth Management Sells 655 Shares of Eli Lilly and Co (LLY)
Code Waechter LLC Buys 115 Shares of Eli Lilly and Co (LLY)
Code Waechter LLC Buys 115 Shares of Eli Lilly and Co (LLY)
Foster Victor Wealth Advisors, LLC Buys 1,127 Shares of Eli Lilly and Co (LLY)
Foster Victor Wealth Advisors, LLC Buys 1,127 Shares of Eli Lilly and Co (LLY)
Reyes Financial Architecture, Inc. Buys 179 Shares of Eli Lilly and Co (LLY)
Reyes Financial Architecture, Inc. Buys 179 Shares of Eli Lilly and Co (LLY)
SeaBridge Investment Advisors LLC Buys 237 Shares of Eli Lilly and Co (LLY)
SeaBridge Investment Advisors LLC Buys 237 Shares of Eli Lilly and Co (LLY)
My Top AI Healthcare Stock to Buy and Hold for 20 Years
Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its strong innovative capabilities.
Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog
Should You Dump Eli Lilly's Shares After This Setback?
The company got some bad news to start 2026.
Goldman Sachs Strategic Factor Allocation Fund Buys 13,479 Shares of Eli Lilly and Co (LLY)
Goldman Sachs Strategic Factor Allocation Fund Buys 13,479 Shares of Eli Lilly and Co (LLY)
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
NEW YORK and NEW ORLEANS, Jan. 23, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
Novo Nordisk A/S ' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week o...